Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures (BRITE)

July 14, 2022 updated by: UCB Pharma

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures

This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
768

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Expanded Access

Expanded Access

A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved by the U.S. Food and Drug Administration (FDA). Also called compassionate use. There are different expanded access types.
Available

Available

  • Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
  • No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
  • Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
  • Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
 outside the clinical trial. See expanded access record.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Innsbruck, Austria
        • 202
      • Linz, Austria
        • 201
      • Wien, Austria
        • 200
      • Wien, Austria
        • 203
  • Belgium
      • Hechteleksel, Belgium
        • 226
      • Leuven, Belgium
        • 227
      • Liege, Belgium
        • 228
  • Brazil
      • Belo Horizonte, Brazil
        • 104
      • Florianopolis, Brazil
        • 100
      • Riberao Preto, Brazil
        • 103
      • Sao Paulo, Brazil
        • 101
  • Bulgaria
      • Blagoevrad, Bulgaria
        • 294
      • Sofiya, Bulgaria
        • 286
      • Sofiya, Bulgaria
        • 287
  • Canada
    • Alberta
      • Calgary, Alberta, Canada
        • 075
    • Ontario
      • London, Ontario, Canada
        • 078
      • Toronto, Ontario, Canada
        • 076
    • Quebec
      • Greenfield Park, Quebec, Canada
        • 077
      • Montreal, Quebec, Canada
        • 079
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada
        • 080
  • Czechia
      • Kromeriz, Czechia
        • 916
      • Ostrava, Czechia
        • 251
      • Ostrava, Czechia
        • 256
      • Ostrava Poruba, Czechia
        • 913
      • Praha 1, Czechia
        • 252
      • Praha 4, Czechia
        • 253
      • Zlin, Czechia
        • 250
  • Estonia
      • Tallinn, Estonia
        • 650
      • Tallinn, Estonia
        • 652
      • Tallinn, Estonia
        • 653
      • Tartu, Estonia
        • 651
  • Finland
      • Kuopio, Finland
        • 275
      • Oulu, Finland
        • 278
      • Tampere, Finland
        • 276
      • Turku, Finland
        • 277
  • France
      • Bethune, France
        • 301
      • Marseille, France
        • 308
      • Montpellier, France
        • 305
  • Germany
      • Berlin, Germany
        • 329
      • Bernau, Germany
        • 326
      • Bielefeld, Germany
        • 332
      • Erlangen, Germany
        • 902
      • Goettingen, Germany
        • 331
      • Kehl-Kork, Germany
        • 904
      • Kiel, Germany
        • 327
      • Marburg, Germany
        • 900
      • Muenchen, Germany
        • 335
      • Osnabruck, Germany
        • 334
      • Ravensburg, Germany
        • 330
      • Ulm, Germany
        • 328
  • Hong Kong
      • Hong Kong, Hong Kong
        • 701
      • Shatin, Hong Kong
        • 700
  • Hungary
      • Budapest, Hungary
        • 410
      • Budapest, Hungary
        • 411
      • Budapest, Hungary
        • 412
      • Debrecen, Hungary
        • 414
      • Kecskemet, Hungary
        • 413
  • India
      • Bangalore, India
        • 726
      • Madurai, India
        • 729
    • Andhra Pradesh
      • Hyderabad, Andhra Pradesh, India
        • 727
    • Maharashtra
      • Nashik, Maharashtra, India
        • 731
    • Maharastra
      • Mumbai, Maharastra, India
        • 725
      • Mumbai, Maharastra, India
        • 728
  • Italy
      • Bari, Italy
        • 378
      • Firenze, Italy
        • 380
      • Milano, Italy
        • 379
      • Napoli, Italy
        • 386
      • Perugia, Italy
        • 376
      • Pisa, Italy
        • 375
      • Pozzilli, Italy
        • 383
      • Reggio Calabria, Italy
        • 384
      • Torino, Italy
        • 382
    • Cagliari
      • Monserrato, Cagliari, Italy
        • 377
  • Japan
      • Hiroshima, Japan
        • 855
      • Itami-city, Japan
        • 852
      • Osaka, Japan
        • 850
      • Shizuoka, Japan
        • 851
      • Yokohama-City, Japan
        • 854
  • Korea, Republic of
      • Busan, Korea, Republic of
        • 753
      • Gwangju, Korea, Republic of
        • 752
      • Seoul, Korea, Republic of
        • 750
      • Seoul, Korea, Republic of
        • 751
      • Seoul, Korea, Republic of
        • 754
  • Latvia
      • Daugapils, Latvia
        • 627
      • Jekabpils, Latvia
        • 629
      • Riga, Latvia
        • 626
      • Riga, Latvia
        • 628
      • Valmiera, Latvia
        • 625
  • Lithuania
      • Alytus, Lithuania
        • 425
      • Kaunas, Lithuania
        • 427
      • Vilnius, Lithuania
        • 426
  • Mexico
      • Aguascalientes, Mexico
        • 129
      • Culiacan, Mexico
        • 127
      • Distrito Federal, Mexico
        • 125
      • Mexico D.F., Mexico
        • 130
    • Jalisco
      • Guadalajara, Jalisco, Mexico
        • 126
      • Guadalajara, Jalisco, Mexico
        • 128
  • Netherlands
      • Heemstede, Netherlands
        • 401
      • Heeze, Netherlands
        • 400
      • Zwolle, Netherlands
        • 403
  • Poland
      • Bialystok, Poland
        • 475
      • Gdansk, Poland
        • 485
      • Gdansk, Poland
        • 791
      • Katowice, Poland
        • 478
      • Katowice, Poland
        • 480
      • Katowice, Poland
        • 481
      • Krakow, Poland
        • 476
      • Krakow, Poland
        • 793
      • Lublin, Poland
        • 483
      • Poznan, Poland
        • 479
      • Poznan, Poland
        • 477
      • Poznan, Poland
        • 482
      • Warszawa, Poland
        • 488
  • Puerto Rico
      • San Juan, Puerto Rico
        • 038
  • Russian Federation
      • Kazan, Russian Federation
        • 501
      • Kazan, Russian Federation
        • 506
      • Moscow, Russian Federation
        • 502
      • Moscow, Russian Federation
        • 503
      • Moscow, Russian Federation
        • 505
      • Nizhny Novgorod, Russian Federation
        • 509
      • Smolensk, Russian Federation
        • 508
  • Spain
      • Badalona, Spain
        • 536
      • Barcelona, Spain
        • 528
      • Barcelona, Spain
        • 529
      • Barcelona, Spain
        • 535
      • Barcelona, Spain
        • 540
      • San Sebastian, Spain
        • 539
      • Santiago de Compostela, Spain
        • 532
      • Valencia, Spain
        • 527
      • Valencia, Spain
        • 537
      • Valladolid, Spain
        • 526
  • Sweden
      • Goteborg, Sweden
        • 551
      • Linkoping, Sweden
        • 552
      • Stockholm, Sweden
        • 550
  • Taiwan
      • Kaohsiung City, Taiwan
        • 806
      • Taichung, Taiwan
        • 801
      • Tainan, Taiwan
        • 800
      • Taoyuan Hsien, Taiwan
        • 803
  • United Kingdom
      • Birmingham, United Kingdom
        • 603
      • Cardiff, United Kingdom
        • 606
      • Cornwall, United Kingdom
        • 601
      • London, United Kingdom
        • 600
      • Middlesborough, United Kingdom
        • 605
      • Newcastle, United Kingdom
        • 607
      • Salford, United Kingdom
        • 608
      • Swansea, United Kingdom
        • 602
  • United States
    • Arizona
      • Phoenix, Arizona, United States
        • 001
      • Phoenix, Arizona, United States
        • 013
      • Tucson, Arizona, United States
        • 006
    • Arkansas
      • Little Rock, Arkansas, United States
        • 775
    • California
      • Sacramento, California, United States
        • 045
      • San Francisco, California, United States
        • 025
    • Colorado
      • Aurora, Colorado, United States
        • 060
      • Colorado Springs, Colorado, United States
        • 085
    • Florida
      • Miami, Florida, United States
        • 071
      • Miami, Florida, United States
        • 110
      • Naples, Florida, United States
        • 073
      • Ocala, Florida, United States
        • 090
      • Orlando, Florida, United States
        • 027
      • Port Charlotte, Florida, United States
        • 064
      • Sarasota, Florida, United States
        • 044
    • Georgia
      • Atlanta, Georgia, United States
        • 023
      • Atlanta, Georgia, United States
        • 063
      • Columbus, Georgia, United States
        • 062
      • Rome, Georgia, United States
        • 048
    • Idaho
      • Boise, Idaho, United States
        • 039
    • Illinois
      • Peoria, Illinois, United States
        • 005
      • Winfield, Illinois, United States
        • 017
    • Iowa
      • Ames, Iowa, United States
        • 020
      • Iowa City, Iowa, United States
        • 069
    • Kentucky
      • Lexington, Kentucky, United States
        • 780
    • Louisiana
      • Hammond, Louisiana, United States
        • 092
    • Maryland
      • Bethesda, Maryland, United States
        • 008
      • Waldorf, Maryland, United States
        • 068
    • Michigan
      • East Lansing, Michigan, United States
        • 055
    • Minnesota
      • Golden Valley, Minnesota, United States
        • 009
    • Montana
      • Missoula, Montana, United States
        • 051
    • New Hampshire
      • Lebanon, New Hampshire, United States
        • 032
    • New Jersey
      • Hamilton, New Jersey, United States
        • 042
      • Voorhees, New Jersey, United States
        • 058
    • New York
      • Kingston, New York, United States
        • 095
      • New York, New York, United States
        • 022
      • New York, New York, United States
        • 099
      • Poughkeepsie, New York, United States
        • 098
    • North Carolina
      • Asheville, North Carolina, United States
        • 010
      • Durham, North Carolina, United States
        • 003
    • Ohio
      • Canton, Ohio, United States
        • 096
      • Cleveland, Ohio, United States
        • 034
      • Columbus, Ohio, United States
        • 070
      • Toledo, Ohio, United States
        • 002
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
        • 043
      • Oklahoma City, Oklahoma, United States
        • 091
      • Tulsa, Oklahoma, United States
        • 054
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States
        • 015
    • South Carolina
      • Charleston, South Carolina, United States
        • 028
      • Port Royal, South Carolina, United States
        • 021
    • Texas
      • Arlington, Texas, United States
        • 050
      • Austin, Texas, United States
        • 061
      • Dallas, Texas, United States
        • 011
      • Dallas, Texas, United States
        • 035
      • Houston, Texas, United States
        • 049
    • Virginia
      • Charlottesville, Virginia, United States
        • 036
    • Washington
      • Seattle, Washington, United States
        • 033
      • Spokane, Washington, United States
        • 056
    • Wisconsin
      • Madison, Wisconsin, United States
        • 052
      • Milwaukee, Wisconsin, United States
        • 057
    • Wyoming
      • Casper, Wyoming, United States
        • 089

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

12 years to 76 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Well-characterized focal epilepsy/epileptic syndrome according to the 1989 International League Against Epilepsy (ILAE) classification
  • Presence of an EEG reading compatible with the clinical diagnosis of focal epilepsy within the last 5 years
  • Presence of a brain MRI/computed tomography (CT) scan performed within the last 2 years
  • Subjects having at least 8 Type I seizures [POS; focal seizures (according to the 1981 ILAE classification)] during the 8-week Baseline Period with at least 2 Type I seizures during each 4-week interval of the Baseline Period
  • Subjects having at least 2 partial onset seizures whether or not secondarily generalized per month during the 3 months preceding V1
  • Subjects being uncontrolled while treated by 1 or 2 permitted concomitant AED(s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED
  • Permitted concomitant AED(s) and VNS being stable and at optimal dosage for the subject from at least 1 month (3 months for phenobarbital, phenytoin, and primidone) before V1 and expected to be kept stable during the Baseline and Treatment Period. Benzodiazepine taken more than once a week (for any indication) will be considered as a concomitant AED

Exclusion Criteria:

  • Subject previously randomized within this study or any other prior study with BRV as a dosing arm
  • Seizure type IA (1981 ILAE classification) nonmotor as only seizure type.
  • Subject is currently treated with LEV or has taken LEV within 90 days prior to V1
  • Subject has any medical or psychiatric condition, obvious cognitive impairment or mental retardation that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • Subjects whose seizures could not be reliably counted on a regular basis due to their fast and repetitive occurrence (clusters or flurries)
  • Subject has history or presence of status epilepticus during the year preceding V1 or during Baseline
  • Subject has history or presence of known psychogenic nonepileptic seizures
  • Subject on felbamate with less than 18 months exposure before V1
  • Subject currently on vigabatrin. Subject with history of vigabatrin use but either no visual fields examination report available including standard static (Humphrey or Octopus) or kinetic perimetry (Goldman) or results of these examinations are abnormal
  • Subject taking any drug with possible central nervous system (CNS) effects except if stable from at least 1 month before V1 and expected to be kept stable during the Treatment Period
  • Subject has history of cerebrovascular accident, including transient ischemic attack, in the last 6 months
  • Subject is suffering from severe cardiovascular disease or peripheral vascular disease
  • Subject has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months
  • Subject has ongoing psychiatric disease other than mild controlled disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Matching placebo tablets administered twice daily
Drug: Placebo
Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
Drug: Antiepileptic drugs with market authorization available per country
Experimental: Brivaracetam 100 mg/ day
Brivaracetam 50 mg/ day administered twice daily.
Drug: Antiepileptic drugs with market authorization available per country
Drug: Brivaracetam
Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
Drug: Brivaracetam
Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
Experimental: Brivaracetam 200 mg/ day
Brivaracetam 100 mg/ day administered twice daily
Drug: Antiepileptic drugs with market authorization available per country
Drug: Brivaracetam
Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
Drug: Brivaracetam
Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration
Time Frame: 12 week Treatment Period
Primary endpoint: United States of America (FDA)
12 week Treatment Period
50% Responder Rate for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration
Time Frame: Baseline to 12 week Treatment Period
Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration.
Baseline to 12 week Treatment Period

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Percent Change in Partial Onset Seizure (Type I) Frequency From the Baseline to the Treatment Period
Time Frame: Baseline to 12 week Treatment Period
Baseline to 12 week Treatment Period
Categorized Percent Reduction Form Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the Treatment Period
Time Frame: Baseline to 12 week Treatment Period
Baseline to 12 week Treatment Period
Seizure Freedom Rate (All Seizure Types) During the 12-week Treatment Period
Time Frame: 12 week Treatment Period
12 week Treatment Period
All Seizure Frequency (Type I + II + III) During the 12-week Treatment Period
Time Frame: 12 week Treatment Period
12 week Treatment Period
Time to the First Type I Seizure During the Treatment Period
Time Frame: 12 week Treatment Period
12 week Treatment Period
Time to the Fifth Type I Seizure During the Treatment Period
Time Frame: 12 week Treatment Period
12 week Treatment Period
Time to the Tenth Type I Seizure During the Treatment Period
Time Frame: 12 week Treatment Period
12 week Treatment Period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
UCB Pharma

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2010

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2014

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2014

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 9, 2010

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 15, 2010

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 16, 2010

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 22, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 14, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • N01358
  • 2010-019361-28 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings